On November 16, Twist Bioscience Corp fell 5.83% in Pre-Market Trading, trading at $108.16 per share, with turnover of $105,600.
The latest catalyst in public information is renewed pressure from analyst target-price cuts after the company’s recent earnings release, alongside investor focus on management’s indication of slower growth in fiscal 2027, particularly in AI drug discovery.
Recent reports show Guggenheim cut its price target to $150 from $212. This followed Twist Bioscience Corp’s fiscal Q4 results released on November 12: revenue rose to $126.6 million from $99.0 million a year earlier, ahead of the $123.5 million consensus, while loss per share narrowed to $0.32 from $0.45, better than the expected $0.39 loss. Fiscal Q1 revenue guidance of $130 million to $132 million and fiscal 2027 revenue guidance of $550 million to $560 million were also slightly above consensus, but the market remained focused on signals of a sharp slowdown in 2027 growth, which continued to weigh on sentiment despite the quarterly beat.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments